To review the basis for the use of oral tetracyclines in ocular rosacea.
Review of the published literature.
Two prospective, masked, and placebo-controlled studies of oxytetracycline for ocular rosacea demonstrated a modest treatment benefit. Studies performed with tetracycline and doxycycline for ocular rosacea were not placebo controlled, and the optimal drug, dose, and schedule of administration were not evaluated.
Available evidence supports a moderate treatment benefit in ocular rosacea for oxytetracycline, a tetracycline derivative not currently available in the United States. The efficacies of doxycycline and tetracycline, including treatment effect, optimal dose, duration of therapy, and side effects when used for ocular rosacea have not been established.
From the Molecular Pathogenesis of Eye Infection Research Center, Dean A. McGee Eye Institute, Departments of Ophthalmology (Drs. Stone and Chodosh) and Cell Biology (Dr. Chodosh), University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Received for publication May 8, 2003;
revision received August 6, 2003; accepted August 8, 2003.
Supported in part by a Lew R. Wasserman Merit Award to J.C. from Research to Prevent Blindness, Inc., New York, NY.
Reprints: James Chodosh, MD, DMEI-OUHSC, 608 Stanton L. Young Blvd., Oklahoma City, OK 73104 (e-mail: email@example.com).